Protas Clinical Trials Management Platform

Descriptions

Protas, a non-profit organisation, will facilitate the development of better treatments for common diseases and improve public health outcomes by combining smart randomized trial design with effective technology and collaborative partnerships. Protas seeks to engage a provider to develop and deploy a new, globally available, first in class Integrated Clinical Trials Management Platform. The expected indicative timeline is as follows: - December 2021-January 2022: Market engagement RFI Exercise - Q2 2022: Contract notice, supplier selection and tendering - Q4 2022: Contract award, requirements decomposition, design, development, and deployment - Q3/Q4 2023: New integrated platform (Release 1) goes live - Q4 2023: Initial support and transition This PIN and the accompanying Request for Information (RFI) announce the start of Protas' early market engagement for a clinical trials management platform. The RFI sets out the context and requirements of a future unified clinical trials management platform. The RFI includes questions at the end of the document that interested suppliers are invited to respond to. The objectives of this market engagement RFI exercise are to: - Inform the marketplace of Protas's upcoming requirement; - Understand potential solution options and service delivery approaches; and - Identify and understand potential commercial arrangements. The RFI document is linked to this PIN and available via the Protas supplier data room. Further information about this anticipated future procurement can be found in the Request for Information (RFI) document accompanying this notice. All information in the accompanying RFI document is provided in good faith but is indicative only and does not constitute an invitation to tender or an offer of contract.